Infections

All Conditions

Symptoms and General Pathology

Neoplasms

Digestive System Diseases

Rare Diseases

Communicable Diseases

Stomach Neoplasms

Atrophy

Gastritis, Atrophic

Gastritis

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Stomach Diseases

Pathological Conditions, Anatomical

Gastroenteritis

Stomach Cancer

Patients with histologically confirmed gastric cancer (adenocarcinoma) planned for surgical management

Patients with histologically confirmed gastric cancer (adenocarcinoma)

Patients without gastric malignant disease according to data obtained in upper endoscopy

Average risk population of both genders aged 40-64 at the time of inclusion lacking alarm symptoms for gastrointestinal cancer

Patients with dyspeptic symptoms or other complains being referred for upper endoscopy (Chile)

Breath sampling will be performed by using a special sensor device and or GC-MS analysis (by collecting breath samples in adsorbent tubes). Pepsinogen testing will be used in a subgroup to identify serological increased risk for atrophy

Breath sampling for VOC detection

Only for gastric cancer patients undergoing surgery (Group 1)

Surgery material collection for VOC headspace analysis

Routine endoscopic evaluation with a standard biopsy work-up according to updated Sydney system. Additional gastric contents for GC-MS and microbiota analysis in a subgroup. Endoscopy will be used only according to the clinical indications (in Group 4 - according to the results of pepsinogen tests)

Upper endoscopy

Faecal and gastric contents and biopsy samples for microbiota testing

Microbiota testing

Marcis Leja, MD, PhD

Daiga Santare, MD, PhD

Emmanuel Dias Neto, MD, PhD

Robinson Gonzalez, MD, PhD

Alejandro Corvalan, MD, PhD

Raul Murillo, MD, PhD

Andrii Lukashenko, MD, PhD

Hossam Haick, PhD

The study is aimed to determine the potential of volatile marker testing for gastric cancer screening.

The study will be addressing the role of confounding factors, including lifestyle factors, diet, smoking as well as addressing the potential role of microbiota in the composition of exhaled volatile markers.

Patients with established disease (gastric cancer, precancerous lesions) as well as patients investigated for the lesions and having been documented lack of the lesions will be enrolled to the study at clinical sites in Europe (Latvia, Ukraine) and Latin America (Colombia, Chile, Brazil). In addition, group of persons from general population at average risk for developing the target disease and individuals being referred for upper endoscopy according to clinical indications will be also enrolled.

Testing of volatile markers will be conducted by one of two methods: 1) gas chromatography coupled to mass spectroscopy (GS-MS) and 2) sensor technology. Various sensors will be used and evaluated for the purpose.

The potential sources of volatile organic compounds (VOCs) in the breath will be addressed by studying VOC emission by using headspace analysis from cancer tissue, gastric contents, cancer cell cultures and H.pylori.

The potential role of gastric and faecal microbiota in the origin of VOCs in the breath will be addressed. Metabolome in the circulation will also get correlated to VOCs in the breath and with microbiome.

Exhaled air samples being stored in specific adsorbent media Plasma/serum samples for group stratification Biopsy samples from stomach for histological assessment and microbiota analysis Gastric content samples for GC-MS and microbiota analysis Faecal samples for occult blood testing and microbiota analysis

Screening of Gastric Cancer Via Breath Volatile Organic Compounds by Hybrid Sensing Approach

The role of confounding factors will be addressed to address their role in VOC emission

The characteristic VOC pattern based on sensor analysis and its performance indicators will be detected

Identification of specific chemistries (GC-MS analysis) originating from gastric cancer

Comparative analysis between the performance of different sensor performance in target disease identification

Analysis of the role of gastric and faecal microbiota in the origin of VOCs in the exhaled breath

Spots Global Cancer Trial Database for surgery material collection for voc headspace analysis